A Prospective, Observational Study in Adults With Retinitis Pigmentosa (RP)

Eligibility Criteria

• * Subject is ≥ 18 years of age at the time of informed consent.
• * Subject has a clinical diagnosis of nonsyndromic retinitis pigmentosa.
• * Subject is willing to consent to genetic testing, if not already done.
• * Subject has BCVA in the worse eye between hand motion and 35 Early Treatment of Diabetic Retinopathy Study (ETDRS) letter score (approximately ≤ 20/200 Snellen equivalent), inclusive.
• * Subject has a central visual field diameter (ie, excluding temporal islands) of \< 20 degrees in the worse eye as measured with the V4e stimulus using kinetic perimetry.
• * Subject has an eye disease or visual disorder other than retinitis pigmentosa that impairs visual function.
• * Subject has any other eye condition, which in the opinion of the Investigator, would preclude an accurate evaluation at any time during the study.
• * Subject has any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study.
• * Subject has received treatment with any nonapproved, experimental, or investigational therapy in either eye (systemic, topical, intravitreal) and/or received treatment in an interventional clinical trial for an eye disease or disorder within 90 days or 5 half-lives, whichever is longer, prior to Screening or anticipates the need to receive treatment in an interventional clinical trial during their participation in this study.
• * Subject has previously received cell therapy, gene augmentation therapy, genome editing therapy, or any subretinal administered therapy for an eye disease or disorder or anticipates the need for these therapies during their participation in this study.
• * Subject has previously received LUXTURNA (voretigene neparvovec-rzyl) or anticipates the need for this therapy during their participation in this study.